Cannabis could help alleviate depression and suicidality among people with PTSD

Cannabis may be helping Canadians cope with the effects of post-traumatic stress disorder (PTSD), new research suggests. In an analysis of health survey data collected by Statistics Canada from more than 24,000 Canadians, researchers from the BC Centre on Substance Use (BCCSU) and University of British Columbia (UBC) found that people who have PTSD but do not medicate with cannabis are far more likely to suffer from severe depression and have suicidal thoughts than those who reported cannabis use over the past year.

The study, published today in the Journal of Psychopharmacology, is the first to document the relationships between PTSD, cannabis use, and severe mental health outcomes in a sample representative of the population.

"We know that with limited treatment options for PTSD, many patients have taken to medicating with cannabis to alleviate their symptoms," says lead author Stephanie Lake, a research assistant at the BCCSU and PhD candidate at UBC's school of population and public health. "However, this is the first time that results from a nationally representative survey have shown the potential benefits of treating the disorder with cannabis."

Data was obtained from Statistics Canada's 2012 Canadian Community Health Survey - Mental Health (CCHS-MH), which covers Canadians aged 15 and older. Among 24,089 eligible respondents, 420 reported a current clinical diagnosis of PTSD. In total, 106 people with PTSD, or 28.2 per cent, reported past-year cannabis use, compared to 11.2 per cent of those without PTSD.

The researchers found that PTSD was significantly associated with a recent major depressive episode and suicidal ideation among people who don't use cannabis. Specifically, cannabis non-users with PTSD were about seven times more likely to have experienced a recent major depressive episode and 4.7 times more likely to have thoughts of suicide compared to cannabis non-users without PTSD, the researchers found.

Among cannabis-using respondents, PTSD was not associated with a recent depressive episode or suicide ideation. Over one-quarter of Canadians with PTSD reported past-year cannabis use, which is remarkably high compared to the prevalence of recent use in the general Canadian population (estimated at 11.4 per cent in the present study).

People exposed to trauma, including survivors of acute injury, conflict, violence and disaster, suffer from depression, suicide, and substance use disorders at disproportionately high rates compared to the general population. Canada is estimated to have one of the highest prevalence rates of PTSD worldwide, affecting an estimated 9.2 per cent of the population.

"We're only just beginning to understand what the therapeutic potential of cannabis may be for a variety of health conditions," says senior author Dr. M-J Milloy, research scientist at BCCSU and Canopy Growth Professor of Cannabis Science at UBC. "These findings are promising, and merit further study in order to fully understand the benefits of cannabis for people living with PTSD."

Stephanie Lake, Thomas Kerr, Jane Buxton,  Zach Walsh, Brandon Marshall, Evan Wood, M-J Milloy.
Does cannabis use modify the effect of post-traumatic stress disorder on severe depression and suicidal ideation? Evidence from a population-based cross-sectional study of Canadians.
Journal of Psychopharmacology, November 5, 2019. doi: 10.1177/0269881119882806.

Most Popular Now

A step closer to cancer precision medicine

Researchers from the Faculty of Medicine and the Institute for Molecular Medicine (FIMM) at the University of Helsinki have developed a computational model, Combined Esse...

Artificial Intelligence algorithm can learn the la…

Artificial Intelligence can be used to predict molecular wave functions and the electronic properties of molecules. This innovative AI method developed by a team of resea...

Amgen completes acquisition of Otezla® (apremilast…

Amgen (NASDAQ:AMGN) today announced the successful completion of its acquisition of worldwide rights to Otezla® (apremilast), the only oral, non-biologic treatment for mo...

Bristol-Myers Squibb completes acquisition of Celg…

Bristol-Myers Squibb Company (NYSE:BMY) has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all governmen...

Amgen and the Duke Clinical Research Institute ann…

Amgen (NASDAQ:AMGN) in collaboration with the Duke Clinical Research Institute (DCRI) announced plans to initiate the Cardiovascular Multi-dimensional Observational Inves...

Statins not associated with memory or cognition de…

Given consumer concern that statins may be associated with memory or cognitive decline, a new study published today in the Journal of the American College of Cardiology m...

Novartis announces new strategy to provide innovat…

Novartis announced a new strategy to broaden patient reach and availability of its portfolio of medicines in sub-Saharan Africa (SSA), which is home to the largest unders...

New advances in the treatment of advanced lung can…

The University of Barcelona (UB) and Hospital Clínic de Barcelona collaborate with Boehringer Ingelheim Inc. to improve the efficiency of nintedanib, an antiangiogenic an...

FDA grants priority review to Roche’s risdiplam fo…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Review for ...

A protein tag to study the immune system

Researchers from VIB-UGent Center for Medical Biotechnology, University of Iowa (USA) and other collaborators, developed a novel approach to better understand a basic def...

Bayer and Dewpoint Therapeutics partner to researc…

Bayer and Dewpoint Therapeutics, a biotechnology company with sites in Boston and Dresden, Germany, today announced an option, research and license agreement worth up to ...

Pharmacist-led interventions may help prevent card…

With their expertise in the safe and effective use of medications, pharmacists can help in the management of chronic diseases. A review and analysis published in the Brit...